Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110133 | 0.98 | MAPT (0.57) | MAPTABCC4ALDH1A1LMNACHRNB2 | |
| SCHEMBL3112734 | 0.98 | MAPT (0.57) | MAPTABCC4ALDH1A1LMNACHRNB2 | |
| SCHEMBL3112942 | 0.98 | MAPT (0.57) | MAPTABCC4ALDH1A1LMNACHRNB2 | |
| SCHEMBL3118989 | 0.98 | MAPT (0.57) | MAPTABCC4ALDH1A1LMNACHRNB2 | |
| SCHEMBL3112105 | 0.98 | MAPT (0.57) | MAPTABCC4ALDH1A1LMNACHRNB2 | |
| SCHEMBL3113047 | 0.93 | ALDH1A1 (0.54) | MAPTABCC4ALDH1A1LMNACHRNB2 | |
| SCHEMBL622807 | 0.84 | — | — | |
| SCHEMBL131476 | 0.81 | ALDH1A1 (0.74) | ALDH1A1LMNACHRNB2CHRNB4CHRNA4 | |
| SCHEMBL630594 | 0.80 | ALDH1A1 (0.55) | MAPTABCC4ALDH1A1LMNATSHR | |
| SCHEMBL16802992 | 0.80 | EPHX2 (0.54) | MAPTABCC4ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168385-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | ACHILLE LIFE SCIENCES LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| WO-2022115651-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | HEPION PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| CN-113166091-A | Pladienolide compounds and uses thereof | 卫材R&D管理有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3461835-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ContraVir Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2018106928-A1 | TREATMENT AND PREVENTION OF HBV DISEASES BY CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACIDES 1 AND 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9714271-B2 | Cyclosporine analogue molecules modified at amino acid 1 and 3 | CONTRAVIR PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| WO-2012079172-A1 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 | ISOTECHNIKA PHARMA INC. (CA) | 2012-06-21 | — | — | WO | disclosed |
| US-7714087-B2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1734061-B1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer and uses thereof | MITSUI CHEMICALS INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010012073-A1 | NONIMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGUE MOLECULES | ISOTECHNIKA LABS INC. (CA) | 2010-02-04 | — | — | WO | disclosed |
| US-20090137757-A1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | IMUTA JUNICHI | 2009-05-28 | — | — | US | disclosed |
| US-7393907-B2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-1734061-A2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20040122192-A1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20020156207-A1 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2002-10-24 | — | — | US | disclosed |
| EP-1186619-A2 | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition contaning the copolymer, and uses thereof | Mitsui Chemicals, Inc. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168385-A1 | USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS | SERPINC1, CHP1, FGB | MAPT 4712/4885ABCC4 1128/4885ALDH1A1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.